0.6872

1.58% -0.011

Rani Therapeutics Holdings Inc (RANI)

Overview News Price History Option Chain Financials Discussions Forecast

Rani Therapeutics Holdings Inc stock is traded at $0.6872, with a volume of 793.59K. It is down -1.58% in the last 24 hours and down -12.23% over the past month. Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Previous Close:

$0.6982

Open:

$0.71

24h Volume:

793.59K

Relative Volume:

0.91

Market Cap:

$77.23M

Revenue:

$3.17M

Net Income/Loss:

$-36.23M

P/E Ratio:

-1.681

EPS:

-0.4088

Net Cash Flow:

$-17.11M

1W Performance:

-10.90%

1M Performance:

-12.23%

6M Performance:

-50.91%

1Y Performance:

+4.07%

1-Day Range:

$0.6701

$0.7264

1-Week Range:

$0.66

$0.8277

52-Week Range:

$0.387

$3.87

Rani Therapeutics Holdings Inc Stock (RANI) Company Profile

Name

Rani Therapeutics Holdings Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(408) 457-3700

Address

2051 RINGWOOD AVENUE, SAN JOSE

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

RANI's Discussions on Twitter

Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RANI Rani Therapeutics Holdings Inc	0.6872	77.23M	3.17M	-36.23M	-17.11M	-0.4088
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Lake Street	Buy
Aug-02-24	Initiated	Oppenheimer	Outperform
Jun-14-24	Initiated	Maxim Group	Buy
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Oct-11-22	Initiated	UBS	Buy
Jul-27-22	Initiated	H.C. Wainwright	Buy
Jun-13-22	Initiated	Wedbush	Outperform

View All

Rani Therapeutics Holdings Inc Stock (RANI) Latest News

Jul 10, 2026

PegBio Partners Rani for Oral Metabolic Disease Drugs - AllSci

Jul 10, 2026

Rani collaborates with Pegbio on oral drug delivery in obesity - BioWorld News

Jul 10, 2026

Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration? - Kalkine Media

Jul 10, 2026

Jul 09, 2026

PegBio Teams with Rani Therapeutics to Pursue Oral Metabolic Therapies - TipRanks

Jul 09, 2026

Rani Therapeutics, PegBio Collaborate on Oral Delivery of Obesity Drugs - Moomoo

Jul 09, 2026

Rani Therapeutics partners with PegBio on obesity drugs - Investing.com

Jul 09, 2026

Rani Therapeutics partners with PegBio on obesity drugs By Investing.com - Investing.com Canada

Jul 09, 2026

Rani widens obesity pipeline with PegBio oral-drug pact - Stock Titan

Jul 09, 2026

Jul 08, 2026

Rani Therapeutics (RANI) CFO Nicholas Maestas files initial Form 3 ownership - Stock Titan

Jul 08, 2026

Rani Therapeutics | 3: Initial statement of beneficial ownership of securities- Maestas Nicholas - Moomoo

Jul 08, 2026

Jul 06, 2026

NMAD Stock Price and Chart — NASDAQ:NMAD - TradingView

Jul 06, 2026

Price to book forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - TradingView

Jul 06, 2026

Jul 02, 2026

Rani Therapeutics Appoints Nicholas Maestas as New Chief Financial Officer Effective June 29, 2026 - Minichart

Jun 30, 2026

New Rani Therapeutics (NASDAQ: RANI) CFO granted options, 2026 inducement plan - Stock Titan

Jun 30, 2026

Jun 29, 2026

Rani Therapeutics Holdings, Inc. Announces Appointment of Nicholas Maestas as Chief Financial Officer, Effective June 29, 2026 - marketscreener.com

Jun 29, 2026

Rani Therapeutics names Nicholas Maestas as CFO - Investing.com

Jun 29, 2026

Rani Therapeutics Names Nicholas Maestas CFO - Moomoo

Jun 29, 2026

Rani Therapeutics names Nicholas Maestas as CFO By Investing.com - Investing.com Nigeria

Jun 29, 2026

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - marketscreener.com

Jun 29, 2026

Press Release: Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - Moomoo

Jun 29, 2026

Jun 28, 2026

Price to earnings forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - TradingView

Jun 28, 2026

Jun 26, 2026

Rani Therapeutics Holdings, Inc. Class A Actuals & Estimates (NASDAQ:RANI) - TradingView

Jun 26, 2026

Jun 25, 2026

RANI Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026